Market Cap
$12.0B
EHC
Encompass Health Corp
$120.52 ▲ +1.23%
Prev close $119.06Market cap$12.0B
ConsensusStrong Buy
12-mo target$148.17 (+22.9%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)28 New Institutional Positions22 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on EHC right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (94%)
Inst. Holders
50 funds
Inst. Value
$6.8B
Inst. Activity
28 buys / 22 sells
Insider Activity
$0.00 buy / $30.7M sell
Insider Net $
-$30.7M
SEC Reports
7
Price chart 30d -0.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 earnings
Sep 1, 2026 SEC Encompass Health announces date of 2026 third-quarter earnings call
BIRMINGHAM, Ala., Oct. 1, 2026 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it
Two EHC insiders (EVP/General Counsel and Chief Accounting Officer) sold a combined ~$1.22M in open-market sales on Augu
CLUSTER — Impact 3/10
Aug 31, 2026 Insider
Price Andrew L sold 5,211 shares
Chief Accounting Officer @ $120.93 ($630.2K)
Aug 31, 2026 Insider
Darby John Patrick acquired via exercise 4,858 shares
EVP, Gen Counsel & Secretary @ $35.06 ($170.3K)
Aug 31, 2026 Insider
Aug 11, 2026 SEC Darby John Patrick sold 4,858 shares
EVP, Gen Counsel & Secretary @ $121.09 ($588.3K)
Three top executives at Encompass Health (CEO, CFO, General Counsel) sold a combined ~$3.69M in open-market sales on Aug
CLUSTER — Impact 5/10
Encompass Health reported Q2 2026 diluted EPS of $1.55, beating consensus of $1.48 by 4.7%, and net operating revenue of
PRESS-RELEASE — Impact 7/10
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — DOUBLED
2,563,104 shares ($259.1M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
94% rate it Buy or better · 18 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 10, 2026 | TD Cowen | MAINTAIN | Buy | 56% |
| Aug 7, 2026 | UBS | MAINTAIN | Buy | 55% |
| Aug 7, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Aug 6, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| May 28, 2026 | TD Cowen | INITIATE | Buy | 56% |
| May 5, 2026 | Barclays | MAINTAIN | Overweight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 10 | 1 | 0 | 0 | 94% | |
| Aug 1, 2026 | 7 | 10 | 1 | 0 | 0 | 94% | |
| Jul 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| Jun 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% |
Price targets
Where 12 covering analysts think EHC trades over the next 12 months.
$148.17 +22.9% upside Strong Buy
Current$120.52 Low$140.00 Median$150.00 High$155.00 12 analysts
$140.00$155.00
Analyst rating Strong Buy· 1.1/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
7 SEC filing reports analyzed · 2 bullish, 1 bearish, 0 mixed, 4 neutral · avg impact 4.4/10.
NEUTRALCLUSTER3/10
Two EHC insiders (EVP/General Counsel and Chief Accounting Officer) sold a combined ~$1.22M in open-
Sep 1, 2026
BEARISHCLUSTER5/10
Three top executives at Encompass Health (CEO, CFO, General Counsel) sold a combined ~$3.69M in open
Aug 11, 2026
BULLISHPRESS-RELEASE7/10
Encompass Health reported Q2 2026 diluted EPS of $1.55, beating consensus of $1.48 by 4.7%, and net
Aug 5, 2026
NEUTRALPRESS-RELEASE2/10
Encompass Health announced the date of its Q2 2026 earnings call — results will be reported after ma
Jul 9, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
earnings
Encompass Health announces date of 2026 third-quarter earnings call
BIRMINGHAM, Ala., Oct. 1, 2026 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will report results for its third quarter ended S
Sep 24, 2026
other
Encompass Health expands in Montgomery County, Texas, with first small-format hospital, replacement hospital
BIRMINGHAM, Ala., and CONROE, Texas, Sept. 24, 2026 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced plans to expand inpatient rehab
Sep 7, 2026
dark_pool
Dark Pool: EHC — 0.8M shares, 26,200 trades
Week starting 2026-09-07. Total ATS volume: 762,005 shares across 26,200 trades.
Aug 31, 2026
dark_pool
Dark Pool: EHC — 1.1M shares, 33,094 trades
Week starting 2026-08-31. Total ATS volume: 1,059,600 shares across 33,094 trades.
Aug 24, 2026
dark_pool
Dark Pool: EHC — 1.2M shares, 29,364 trades
Week starting 2026-08-24. Total ATS volume: 1,236,332 shares across 29,364 trades.
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $1.36 | $1.25–$1.45 | 10.7% | +0.0% | 8↑ 4↓ | $1.6B | 12 |
| Next Q | $1.60 | $1.45–$1.67 | 9.9% | +0.0% | 9↑ 1↓ | $1.7B | 12 |
| Current FY | $6.11 | $5.84–$6.20 | 12.2% | +0.0% | 13↑ 0↓ | $6.5B | 13 |
| Next FY | $6.68 | $6.15–$6.88 | 9.2% | +0.0% | 10↑ 2↓ | $7.0B | 13 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $1.362 | — |
| 7d ago | $1.362 | — |
| 30d ago | $1.362 | — |
| 60d ago | $1.356 | +0.006 |
| 90d ago | $1.358 | +0.004 |
Institutional ownership
Which big funds own EHC (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $6.8B total value (67,805,710 shares) as of 2026-Q2. Top holders: Erste, BlackRock,, VANGUARD. Net buying activity: 28 institutions added/increased vs 22 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Erste Asset Management GmbH | 0 | $0.00 | 0.0% | — |
| BlackRock, Inc. | 10,484,385 | $1.1B | 15.5% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4,924,664 | $497.8M | 7.3% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,475,896 | $452.4M | 6.6% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 3,278,739 | $331.4M | 4.8% | — |
| STATE STREET CORP | 3,185,798 | $322.0M | 4.7% | — |
| CITADEL ADVISORS LLC | 2,563,104 | $259.1M | 3.8% | DOUBLED +400.7% |
| FULLER & THALER ASSET MANAGEMENT, INC. | 2,460,657 | $248.7M | 3.6% | — |
| ALLIANCEBERNSTEIN L.P. | 2,471,751 | $239.1M | 3.5% | — |
| TWO SIGMA INVESTMENTS, LP | 2,267,668 | $229.2M | 3.3% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | DOUBLED | 511,887 | 2,563,104 | +400.7% | $259.1M |
| NORGES BANK | NEW | — | 1,154,864 | — | $116.7M |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | ADD | 803,151 | 1,151,085 | +43.3% | $116.4M |
| MORGAN STANLEY | ADD | 896,982 | 1,146,873 | +27.9% | $115.9M |
| AMERICAN CENTURY COMPANIES INC | ADD | 752,053 | 1,050,470 | +39.7% | $106.2M |
| BROWN ADVISORY INC | ADD | 693,149 | 1,012,731 | +46.1% | $102.4M |
| Holocene Advisors, LP | DOUBLED | 150,323 | 977,634 | +550.4% | $98.8M |
| MILLENNIUM MANAGEMENT LLC | ADD | 477,819 | 805,717 | +68.6% | $81.4M |
| JANE STREET GROUP, LLC | DOUBLED | 4,260 | 582,596 | +13576.0% | $58.9M |
| Qube Research & Technologies Ltd | TRIM | 839,807 | 557,885 | -33.6% | $56.4M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
15 insiders, 50 transactions. Net -$30.7M — $0.00 bought, $30.7M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Price Andrew L | Chief Accounting Officer | SELL | 5,211 | $120.93 | $630.2K |
| Aug 31, 2026 | Darby John Patrick | EVP, Gen Counsel & Secretary | EXERCISE | 4,858 | $35.06 | $170.3K |
| Aug 31, 2026 | Darby John Patrick | EVP, Gen Counsel & Secretary | SELL | 4,858 | $121.09 | $588.3K |
| Aug 10, 2026 | Darby John Patrick | EVP, Gen Counsel & Secretary | SELL | 8,906 | $125.95 | $1.1M |
| Aug 10, 2026 | Tarr Mark J | President & CEO | SELL | 1,579 | $126.06 | $199.0K |
| Aug 10, 2026 | Tarr Mark J | President & CEO | SELL | 171,569 | $125.46 | $21.5M |
| Aug 10, 2026 | COLTHARP DOUGLAS E | EVP & Chief Financial Officer | SELL | 18,869 | $125.38 | $2.4M |
| Jul 16, 2026 | Reidy Christopher R | Director | AWARD | 319 | $112.40 | $35.9K |
| Jul 16, 2026 | Christie Edward M III | Director | AWARD | 248 | $112.43 | $27.9K |
| Jul 15, 2026 | Reidy Christopher R | Director | AWARD | 21 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for EHC.
Shares short
3,000,467
Settlement Sep 15, 2026
Change vs prior
-7.4%
Semi-monthly cycle
Days to cover
4.1
At avg daily volume
Of shares outstanding
≈3.0%
Estimate — not % of float
All EHC filing & press-release reports (7)
- CLUSTER reportSep 1, 2026
- CLUSTER reportAug 11, 2026
- PRESS-RELEASE reportAug 5, 2026
- PRESS-RELEASE reportJul 9, 2026
- 8-K reportJun 1, 2026
- 8-K reportMay 15, 2026
- 8-K reportApr 30, 2026